Eli Lilly and Company (NYSE:LLY) Trading 1.4% Higher – Here’s What Happened

Eli Lilly and Company (NYSE:LLY) shares rose 1.4% on Thursday . The company traded as high as $1,079.26 and last traded at $1,056.57. Approximately 3,842,170 shares were traded during trading, a decline of 5% from the average daily volume of 4,030,669 shares. The stock had previously closed at $1,041.79.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Sanford C. Bernstein increased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a report on Monday, November 24th. Scotiabank assumed coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 price target on the stock. CICC Research boosted their price objective on shares of Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a “neutral” rating in a report on Thursday, November 13th. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a research note on Tuesday, December 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday, December 1st. Four investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,141.73.

Eli Lilly and Company Stock Up 1.4%

The company has a debt-to-equity ratio of 1.71, a quick ratio of 1.24 and a current ratio of 1.55. The firm’s fifty day simple moving average is $951.95 and its 200 day simple moving average is $826.51. The stock has a market capitalization of $998.86 billion, a price-to-earnings ratio of 51.69, a P/E/G ratio of 1.32 and a beta of 0.37.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds and other institutional investors have recently bought and sold shares of the company. AIA Group Ltd boosted its position in Eli Lilly and Company by 34.9% during the 3rd quarter. AIA Group Ltd now owns 46,963 shares of the company’s stock worth $35,833,000 after acquiring an additional 12,150 shares during the last quarter. Keel Point LLC lifted its position in shares of Eli Lilly and Company by 0.6% in the third quarter. Keel Point LLC now owns 3,609 shares of the company’s stock worth $2,753,000 after purchasing an additional 21 shares in the last quarter. Garde Capital Inc. lifted its position in shares of Eli Lilly and Company by 1.7% in the third quarter. Garde Capital Inc. now owns 1,632 shares of the company’s stock worth $1,245,000 after purchasing an additional 28 shares in the last quarter. Bourne Lent Asset Management Inc. boosted its holdings in Eli Lilly and Company by 0.4% during the third quarter. Bourne Lent Asset Management Inc. now owns 3,922 shares of the company’s stock worth $2,992,000 after purchasing an additional 15 shares during the last quarter. Finally, Mirabella Financial Services LLP grew its position in Eli Lilly and Company by 112.2% in the third quarter. Mirabella Financial Services LLP now owns 5,365 shares of the company’s stock valued at $4,085,000 after purchasing an additional 2,837 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.